Higher costs and interest rates due to inflation as well as higher credit card debt point toward consumers spending less in areas including health, personal and household care products. C&D is “well-positioned for this trade down” with 40% of its portfolio in value products, says CEO Matthew Farrell.

Consumer health products sector’s earnings reports for July-September period are its first since FDA advisory committee unanimously voted that results of research agency presented show oral phenylephrine at OTC monograph doses is ineffective to treat nasal congestion.

Beauty and consumer health care weren’t among the the consumer packaged goods categories showing private label market-share growth during April-June period. Consumer health industry executives see more spending on private label in some categories but without affecting their results.

Both health, wellness and beauty product marketers on report increased prices helped drive revenue growth during April-June period while also factoring in lower sales volumes.